After finishing at $21.38 in the prior trading day, AnaptysBio Inc (NASDAQ: ANAB) closed at $22.52, up 5.33%. In other words, the price has increased by $+1.14 from its previous closing price. On the day, 470804 shares were traded.
Ratios:
Our goal is to gain a better understanding of ANAB by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 10.87 and its Current Ratio is at 10.87. In the meantime, Its Debt-to-Equity ratio is 3.73 whereas as Long-Term Debt/Eq ratio is at 3.71.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Wedbush on March 12, 2024, Upgraded its rating to Outperform and sets its target price to $34 from $20 previously.
On February 26, 2024, BTIG Research started tracking the stock assigning a Buy rating and target price of $55.
On February 21, 2024, Stifel started tracking the stock assigning a Buy rating and target price of $50.Stifel initiated its Buy rating on February 21, 2024, with a $50 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 25 ’24 when Faga Daniel sold 3,000 shares for $21.42 per share. The transaction valued at 64,268 led to the insider holds 749,087 shares of the business.
Faga Daniel sold 145,940 shares of ANAB for $3,325,185 on Mar 22 ’24. The CEO now owns 752,087 shares after completing the transaction at $22.78 per share. On Feb 16 ’24, another insider, LOUMEAU ERIC J, who serves as the CHIEF LEGAL OFFICER of the company, sold 5,000 shares for $25.00 each. As a result, the insider received 125,000 and left with 3,240 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ANAB now has a Market Capitalization of 604.58M and an Enterprise Value of 231.49M. For the stock, the TTM Price-to-Sale (P/S) ratio is 35.12 while its Price-to-Book (P/B) ratio in mrq is 6.80. Its current Enterprise Value per Revenue stands at 13.49 whereas that against EBITDA is -1.62.
Stock Price History:
The Beta on a monthly basis for ANAB is -0.29, which has changed by 3.49% over the last 52 weeks, in comparison to a change of 27.86% over the same period for the S&P500. Over the past 52 weeks, ANAB has reached a high of $27.50, while it has fallen to a 52-week low of $13.36. The 50-Day Moving Average of the stock is 23.97, while the 200-Day Moving Average is calculated to be 19.95.
Shares Statistics:
The stock has traded on average 292.61K shares per day over the past 3-months and 518.7k shares per day over the last 10 days, according to various share statistics. A total of 26.60M shares are outstanding, with a floating share count of 23.18M. Insiders hold about 13.37% of the company’s shares, while institutions hold 103.32% stake in the company. Shares short for ANAB as of Mar 15, 2024 were 4.14M with a Short Ratio of 14.13, compared to 4.51M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 15.45% and a Short% of Float of 22.65%.
Earnings Estimates
Its stock is currently analyzed by 6 different market analysts. On average, analysts expect EPS of -$1.51 for the current quarter, with a high estimate of -$1.42 and a low estimate of -$1.65, while EPS last year was -$1.58. The consensus estimate for the next quarter is -$1.55, with high estimates of -$1.43 and low estimates of -$1.72.
Analysts are recommending an EPS of between -$5.83 and -$6.95 for the fiscal current year, implying an average EPS of -$6.26. EPS for the following year is -$6.24, with 6 analysts recommending between -$5.29 and -$7.5.
